Skip to main content

Advertisement

Table 3 Demographic and baseline characteristics of the trial subjects

From: Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Characteristics Placebo (n = 58) GC (n = 65) UC-II (n = 63)
Sex ((n) male + (n) female) 28M + 30F 28M + 37F 33M + 30F
Age (years) 53.1 ± 1.02 52.6 ± 1.02 53.5 ± 0.99
Height (cm) 162 ± 1.00 161 ± 1.12 161 ± 0.89
Body weight (kg) 64.5 ± 1.20 66.0 ± 1.13 65.5 ± 1.12
Body mass index (kg/m2) 24.7 ± 0.40 25.5 ± 0.40 25.2 ± 0.37
Kellgren Lawrence radiographic score    
Grade 2 (n) 39 45 42
Grade 3 (n) 19 20 21
Lequesne's Functional Index 7.74 ± 0.12 8.02 ± 0.12 7.90 ± 0.13
Visual analog score (mm) 58.2 ± 0.97 59.1 ± 0.97 58.4 ± 0.99
Total WOMAC score 1382 ± 34.8 1396 ± 31.8 1398 ± 27.9
Mean WOMAC pain 56.9 ± 1.36 57.5 ± 1.33 58.1 ± 1.03
Mean WOMAC physical function 57.9 ± 1.51 58.5 ± 1.37 58.3 ± 1.24
Mean WOMAC stiffness 56.3 ± 1.63 57.3 ± 1.52 58.1 ± 1.32
Knee flexion ROM (°) 114 ± 1.62 114 ± 1.36 114 ± 1.57
Serum CRP (mg/L)a 5.29 ± 1.47 8.15 ± 1.79 3.35 ± 0.58
Serum COMP (ng/mL)b 325.2 ± 30.5 381.2 ± 44.1 334.6 ± 36.5
Synovial IL-6 (ng/mL)c 13.3 ± 4.73 13.9 ± 5.57 15.3 ± 6.04
Synovial MMP-3 (μg/mL)d 4.03 ± 1.20 2.54 ± 0.78 4.86 ± 1.74
  1. Values presented as Mean ± SE
  2. aNumber of subjects used for analyses: 27, placebo; 29, GC; 29, UC-II
  3. bNumber of subjects used for analyses, 54, placebo; 58, GC; 55, UC-II
  4. cNumber of subjects used for analyses, 23, placebo; 24, GC; 21, UC-II
  5. dNumber of subjects used for analyses, 25, placebo; 27, GC; 23, UC-II